MCID: OVR011
MIFTS: 31

Ovarian Mucinous Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Adenocarcinoma

MalaCards integrated aliases for Ovarian Mucinous Adenocarcinoma:

Name: Ovarian Mucinous Adenocarcinoma 12 15 17 74
Mucinous Carcinoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3606
NCIt 51 C5243
UMLS 74 C1335167

Summaries for Ovarian Mucinous Adenocarcinoma

Disease Ontology : 12 An ovary adenocarcinoma that is characterized by the presence of mucin.

MalaCards based summary : Ovarian Mucinous Adenocarcinoma, also known as mucinous carcinoma of ovary, is related to appendix adenocarcinoma and teratoma. An important gene associated with Ovarian Mucinous Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Gastric cancer and Statin Pathway - Generalized, Pharmacokinetics. The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, kidney and appendix.

Related Diseases for Ovarian Mucinous Adenocarcinoma

Diseases related to Ovarian Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 appendix adenocarcinoma 30.6 CDX2 KRT20 KRT7
2 teratoma 30.3 CDX2 KRT7
3 mucinous adenocarcinoma 30.1 CDX2 KRT20 KRT7 MUC2
4 ovarian mucinous neoplasm 29.3 CDX2 KRT20 KRT7 MUC2
5 cystic teratoma 29.3 CDX2 KRT20 KRT7 MUC2
6 mucinous adenocarcinoma of ovary 11.8
7 adenocarcinoma 10.4
8 ovary neuroendocrine neoplasm 10.2 CDX2 KRT7
9 mucinous adenofibroma 10.2 CDX2 KRT7
10 anus adenocarcinoma 10.2 CDX2 KRT7
11 nasal cavity cancer 10.2 CDX2 KRT7
12 nasal cavity adenocarcinoma 10.2 CDX2 KRT7
13 anal canal adenocarcinoma 10.2 CDX2 KRT7
14 mucinous intrahepatic cholangiocarcinoma 10.2 CDX2 MUC2
15 mucinous ovarian cystadenoma 10.2 CDX2 KRT7
16 cystadenocarcinoma 10.2 KRT7 MUC2
17 chronic cholangitis 10.2 CDX2 MUC2
18 anus cancer 10.2 CDX2 KRT7
19 renal adenoma 10.2 AMACR KRT7
20 bile duct mucoepidermoid carcinoma 10.2 KRT7 MUC2
21 mucoepidermoid carcinoma 10.2 KRT7 MUC2
22 clear cell papillary renal cell carcinoma 10.2 AMACR KRT7
23 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2 CDX2 MUC2
24 papillary adenoma 10.2 AMACR KRT7
25 superior mesenteric artery syndrome 10.2 CDX2 MUC2
26 nephrogenic adenoma 10.2 AMACR KRT7
27 vaginal benign neoplasm 10.1 CDX2 KRT20
28 vaginal adenoma 10.1 CDX2 KRT20
29 vaginal tubulovillous adenoma 10.1 CDX2 KRT20
30 villous adenoma 10.1 CDX2 KRT20
31 metanephric adenoma 10.1 AMACR KRT7
32 microinvasive gastric cancer 10.1 CDX2 MUC2
33 kidney benign neoplasm 10.1 AMACR KRT7
34 urethral diverticulum 10.1 AMACR KRT7
35 cystic basal cell carcinoma 10.1 KRT20 KRT7
36 collecting duct carcinoma 10.1 AMACR KRT7
37 seminal vesicle adenocarcinoma 10.1 KRT20 KRT7
38 transverse colon cancer 10.1 KRT20 KRT7
39 malignant syringoma 10.1 KRT20 KRT7
40 papillary transitional carcinoma 10.1 KRT20 KRT7
41 krukenberg carcinoma 10.1 KRT20 KRT7
42 large intestine adenocarcinoma 10.1 KRT20 KRT7
43 linitis plastica 10.1 KRT20 KRT7
44 lung acinar adenocarcinoma 10.1 KRT20 KRT7
45 small cell carcinoma of the bladder 10.1 KRT20 KRT7
46 small cell carcinoma 10.1 KRT20 KRT7
47 suppurative cholangitis 10.1 CDX2 MUC2
48 adenoid squamous cell carcinoma 10.1 KRT20 KRT7
49 intratubular embryonal carcinoma 10.1 KRT20 KRT7
50 intestinal benign neoplasm 10.1 CDX2 MUC2

Graphical network of the top 20 diseases related to Ovarian Mucinous Adenocarcinoma:



Diseases related to Ovarian Mucinous Adenocarcinoma

Symptoms & Phenotypes for Ovarian Mucinous Adenocarcinoma

Drugs & Therapeutics for Ovarian Mucinous Adenocarcinoma

Drugs for Ovarian Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
5 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
6 Immunoglobulins Phase 3,Phase 2,Phase 1
7 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
8 Antimitotic Agents Phase 3,Phase 2,Phase 1
9 Immunoglobulin G Phase 3,Phase 2,Phase 1
10 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
11 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
12 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14 Immunologic Factors Phase 3,Phase 2,Phase 1
15 Antibodies Phase 3,Phase 2,Phase 1
16 Mitogens Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
19 Micronutrients Phase 3
20 Carotenoids Phase 3
21 Trace Elements Phase 3
22 taxane Phase 3
23
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
24
Ipilimumab Approved Phase 2 477202-00-9
25
nivolumab Approved Phase 2 946414-94-4
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
28
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
29
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
30 Immunosuppressive Agents Phase 2
31 Antirheumatic Agents Phase 2
32 Antineoplastic Agents, Alkylating Phase 2
33 Alkylating Agents Phase 2
34
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
35
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093
36
Veliparib Investigational Phase 1 912444-00-9 11960529
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
38
tannic acid Approved Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Not Applicable 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
4 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
5 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
6 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
7 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
8 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
9 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
10 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
11 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
12 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting NCT03476681 Phase 1 NEO-201
13 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
14 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
15 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable

Search NIH Clinical Center for Ovarian Mucinous Adenocarcinoma

Genetic Tests for Ovarian Mucinous Adenocarcinoma

Anatomical Context for Ovarian Mucinous Adenocarcinoma

MalaCards organs/tissues related to Ovarian Mucinous Adenocarcinoma:

42
Ovary, Kidney, Appendix, Endothelial, Thymus, Colon, Small Intestine

Publications for Ovarian Mucinous Adenocarcinoma

Articles related to Ovarian Mucinous Adenocarcinoma:

(show all 11)
# Title Authors Year
1
Anaplastic Carcinoma Arising From Ovarian Mucinous Adenocarcinoma With Massive Cardiopulmonary Metastasis: An Autopsy Case Report. ( 30393058 )
2019
2
Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma. ( 27060927 )
2016
3
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions. ( 26576867 )
2015
4
Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis. ( 25197383 )
2014
5
Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. ( 24487473 )
2014
6
A case of ovarian mucinous adenocarcinoma in a premenarcheal girl. ( 22016113 )
2012
7
Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma. ( 21556953 )
2011
8
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. ( 19926591 )
2010
9
Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. ( 15721446 )
2005
10
An ovarian mucinous adenocarcinoma arising from mature cystic teratoma associated with respiratory type tissue: a case report. ( 15656343 )
2004
11
Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. ( 9158713 )
1997

Variations for Ovarian Mucinous Adenocarcinoma

Cosmic variations for Ovarian Mucinous Adenocarcinoma:

9 (show top 50) (show all 204)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM20640 WEE2 ovary,NS,carcinoma,mucinous carcinoma c.1193G>A p.R398H 7:141724247-141724247 0
2 COSM20669 ULK1 ovary,NS,carcinoma,mucinous carcinoma c.868G>A p.V290M 12:131910720-131910720 0
3 COSM6923559 TSC1 ovary,NS,carcinoma,mucinous carcinoma c.1997+1G>A p.? 9:132905580-132905580 0
4 COSM20712 TRRAP ovary,NS,carcinoma,mucinous carcinoma c.5786G>T p.R1929L 7:98955228-98955228 0
5 COSM10758 TP53 ovary,NS,carcinoma,mucinous carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
6 COSM10662 TP53 ovary,NS,carcinoma,mucinous carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
7 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 0
8 COSM11089 TP53 ovary,NS,carcinoma,mucinous carcinoma c.584T>C p.I195T 17:7674947-7674947 0
9 COSM10705 TP53 ovary,NS,carcinoma,mucinous carcinoma c.586C>T p.R196* 17:7674945-7674945 0
10 COSM10704 TP53 ovary,NS,carcinoma,mucinous carcinoma c.844C>T p.R282W 17:7673776-7673776 0
11 COSM10645 TP53 ovary,NS,carcinoma,mucinous carcinoma c.527G>T p.C176F 17:7675085-7675085 0
12 COSM44571 TP53 ovary,NS,carcinoma,mucinous carcinoma c.581T>G p.L194R 17:7674950-7674950 0
13 COSM10656 TP53 ovary,NS,carcinoma,mucinous carcinoma c.742C>T p.R248W 17:7674221-7674221 0
14 COSM10794 TP53 ovary,NS,carcinoma,mucinous carcinoma c.796G>A p.G266R 17:7673824-7673824 0
15 COSM6932 TP53 ovary,NS,carcinoma,mucinous carcinoma c.733G>A p.G245S 17:7674230-7674230 0
16 COSM46470 TP53 ovary,NS,carcinoma,mucinous carcinoma c.922C>G p.L308V 17:7673606-7673606 0
17 COSM10891 TP53 ovary,NS,carcinoma,mucinous carcinoma c.814G>A p.V272M 17:7673806-7673806 0
18 COSM43568 TP53 ovary,NS,carcinoma,mucinous carcinoma c.772G>T p.E258* 17:7674191-7674191 0
19 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 0
20 COSM10768 TP53 ovary,NS,carcinoma,mucinous carcinoma c.535C>T p.H179Y 17:7675077-7675077 0
21 COSM10893 TP53 ovary,NS,carcinoma,mucinous carcinoma c.824G>A p.C275Y 17:7673796-7673796 0
22 COSM11205 TP53 ovary,NS,carcinoma,mucinous carcinoma c.796G>C p.G266R 17:7673824-7673824 0
23 COSM44769 TP53 ovary,NS,carcinoma,mucinous carcinoma c.755T>C p.L252P 17:7674208-7674208 0
24 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 0
25 COSM10648 TP53 ovary,NS,carcinoma,mucinous carcinoma c.524G>A p.R175H 17:7675088-7675088 0
26 COSM44687 TP53 ovary,NS,carcinoma,mucinous carcinoma c.379T>C p.S127P 17:7675233-7675233 0
27 COSM46117 TP53 ovary,NS,carcinoma,mucinous carcinoma c.580C>G p.L194V 17:7674951-7674951 0
28 COSM44676 TP53 ovary,NS,carcinoma,mucinous carcinoma c.714T>G p.C238W 17:7674249-7674249 0
29 COSM44137 TP53 ovary,NS,carcinoma,mucinous carcinoma c.434T>A p.L145Q 17:7675178-7675178 0
30 COSM11059 TP53 ovary,NS,carcinoma,mucinous carcinoma c.713G>A p.C238Y 17:7674250-7674250 0
31 COSM10725 TP53 ovary,NS,carcinoma,mucinous carcinoma c.701A>G p.Y234C 17:7674262-7674262 0
32 COSM43899 TP53 ovary,NS,carcinoma,mucinous carcinoma c.434T>C p.L145P 17:7675178-7675178 0
33 COSM43690 TP53 ovary,NS,carcinoma,mucinous carcinoma c.592G>A p.E198K 17:7674939-7674939 0
34 COSM11307 TP53 ovary,NS,carcinoma,mucinous carcinoma c.643A>T p.S215C 17:7674888-7674888 0
35 COSM10659 TP53 ovary,NS,carcinoma,mucinous carcinoma c.817C>T p.R273C 17:7673803-7673803 0
36 COSM10660 TP53 ovary,NS,carcinoma,mucinous carcinoma c.818G>A p.R273H 17:7673802-7673802 0
37 COSM10801 TP53 ovary,NS,carcinoma,mucinous carcinoma c.404G>A p.C135Y 17:7675208-7675208 0
38 COSM6913 TP53 ovary,NS,carcinoma,mucinous carcinoma c.783-1G>T p.? 17:7673838-7673838 0
39 COSM43751 TP53 ovary,NS,carcinoma,mucinous carcinoma c.673-1G>A p.? 17:7674291-7674291 0
40 COSM43901 TP53 ovary,NS,carcinoma,mucinous carcinoma c.421T>C p.C141R 17:7675191-7675191 0
41 COSM10733 TP53 ovary,NS,carcinoma,mucinous carcinoma c.574C>T p.Q192* 17:7674957-7674957 0
42 COSM10731 TP53 ovary,NS,carcinoma,mucinous carcinoma c.707A>G p.Y236C 17:7674256-7674256 0
43 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 0
44 COSM44827 TP53 ovary,NS,carcinoma,mucinous carcinoma c.358A>G p.K120E 17:7676011-7676011 0
45 COSM11152 TP53 ovary,NS,carcinoma,mucinous carcinoma c.700T>C p.Y234H 17:7674263-7674263 0
46 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 0
47 COSM20645 TNK2 ovary,NS,carcinoma,mucinous carcinoma c.296G>A p.R99Q 3:195884972-195884972 0
48 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 0
49 COSM20667 TEX14 ovary,NS,carcinoma,mucinous carcinoma c.3363G>T p.K1121N 17:58574207-58574207 0
50 COSM20630 SRPK2 ovary,NS,carcinoma,mucinous carcinoma c.1438C>T p.Q480* 7:105142080-105142080 0

Expression for Ovarian Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Ovarian Mucinous Adenocarcinoma.

Pathways for Ovarian Mucinous Adenocarcinoma

GO Terms for Ovarian Mucinous Adenocarcinoma

Sources for Ovarian Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....